Investigating the structure and dynamics of the PIK3CA wild-type and H1047R oncogenic mutant

PLoS Comput Biol. 2014 Oct 23;10(10):e1003895. doi: 10.1371/journal.pcbi.1003895. eCollection 2014 Oct.

Abstract

The PIK3CA gene is one of the most frequently mutated oncogenes in human cancers. It encodes p110α, the catalytic subunit of phosphatidylinositol 3-kinase alpha (PI3Kα), which activates signaling cascades leading to cell proliferation, survival, and cell growth. The most frequent mutation in PIK3CA is H1047R, which results in enzymatic overactivation. Understanding how the H1047R mutation causes the enhanced activity of the protein in atomic detail is central to developing mutant-specific therapeutics for cancer. To this end, Surface Plasmon Resonance (SPR) experiments and Molecular Dynamics (MD) simulations were carried out for both wild-type (WT) and H1047R mutant proteins. An expanded positive charge distribution on the membrane binding regions of the mutant with respect to the WT protein is observed through MD simulations, which justifies the increased ability of the mutated protein variant to bind to membranes rich in anionic lipids in our SPR experiments. Our results further support an auto-inhibitory role of the C-terminal tail in the WT protein, which is abolished in the mutant protein due to loss of crucial intermolecular interactions. Moreover, Functional Mode Analysis reveals that the H1047R mutation alters the twisting motion of the N-lobe of the kinase domain with respect to the C-lobe and shifts the position of the conserved P-loop residues in the vicinity of the active site. These findings demonstrate the dynamical and structural differences of the two proteins in atomic detail and propose a mechanism of overactivation for the mutant protein. The results may be further utilized for the design of mutant-specific PI3Kα inhibitors that exploit the altered mutant conformation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Class I Phosphatidylinositol 3-Kinases
  • Cluster Analysis
  • Humans
  • Models, Biological
  • Molecular Dynamics Simulation
  • Mutation / genetics*
  • Neoplasm Proteins* / chemistry
  • Neoplasm Proteins* / genetics
  • Neoplasm Proteins* / metabolism
  • Neoplasms
  • Phosphatidylinositol 3-Kinases* / chemistry
  • Phosphatidylinositol 3-Kinases* / genetics
  • Phosphatidylinositol 3-Kinases* / metabolism
  • Protein Binding
  • Surface Plasmon Resonance

Substances

  • Neoplasm Proteins
  • Phosphatidylinositol 3-Kinases
  • Class I Phosphatidylinositol 3-Kinases
  • PIK3CA protein, human

Grants and funding

The initial part of this work was co-funded by the NSRF 2007–2013, the European Regional Development Fund and national resources, under the grant “Cooperation” [No. 09ΣΥN 11-675]. This work has been also supported by a Marie Curie Reintegration Grant (FP7-PEOPLE-2009-RG, No 256533) and an AACR Judah Folkman Fellowship for Cancer Research in Angiogenesis (08-40-18-COUR). TE was partly supported by a Bodossaki Foundation graduate scholarship. MP was also partly supported from a FP7-REGPOT-2008 grant (no 229971). We acknowledge PRACE for awarding us access to the computational facility CURIE at GENCI@CEA, France. This work was also supported by the LinkSCEEM-2 project, funded by the European Commission under the 7th Framework Programme through Capacities Research Infrastructure, INFRA-2010-1.2.3 Virtual Research Communities, Combination of Collaborative Project and Coordination and Support Actions (CP-CSA) under grant agreement no RI-261600. Part of the computational work was performed at BRFAA using a cluster funded from European Economic Area Grant No. EL0084. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.